Page last updated: 2024-10-18

glycine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

glycine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 13 studies

Research Excerpts

ExcerptRelevanceReference
"28 patients with active liver cirrhosis were treated with natural IFN alpha 3-6 MU TIW for 3-17 months (mean, 8 +/- 6)."6.39[Long-term interferon (IFN), neominophagen C (SNMC) combination therapy of active liver cirrhosis type C]. ( Iwabuchi, S; Osada, T; Takatori, M; Yoshida, H, 1994)
"28 patients with active liver cirrhosis were treated with natural IFN alpha 3-6 MU TIW for 3-17 months (mean, 8 +/- 6)."2.39[Long-term interferon (IFN), neominophagen C (SNMC) combination therapy of active liver cirrhosis type C]. ( Iwabuchi, S; Osada, T; Takatori, M; Yoshida, H, 1994)
"Two patients of acute myeloblastic leukemia (M2) with post-transfusional hepatitis (non-A, non-B) were treated with alpha-IFN and high-dose SNMC before allogeneic bone marrow transplantation."1.28[Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis]. ( Fujimoto, H; Fukuhara, T; Hashino, S; Imamura, M; Karino, Y; Kobayashi, H; Matsushima, T; Sakurada, K; Tanaka, M; Yoshida, J, 1989)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19901 (7.69)18.7374
1990's3 (23.08)18.2507
2000's2 (15.38)29.6817
2010's6 (46.15)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Zagefka, H1
Huynh, HP1
Senger, AR1
Derington, CG1
Colantonio, LD1
Herrick, JS1
Cook, J1
King, JB1
Rosenson, RS1
Poudel, B1
Monda, KL1
Navar, AM1
Mues, KE1
Stevens, VW1
Nelson, RE1
Vanneman, ME1
Muntner, P1
Bress, AP1
Ma, B1
Ren, G1
Xu, J1
Yin, C1
Shi, Y1
Rahsepar, AA1
Bluemke, DA1
Habibi, M1
Liu, K1
Kawel-Boehm, N1
Ambale-Venkatesh, B1
Fernandes, VRS1
Rosen, BD1
Lima, JAC1
Carr, JC1
Freitag, TM1
Chen-Sankey, JC1
Duarte, DA1
Ramsey, MW1
Choi, K1
Winkler-Heil, R1
Hussain, M1
Hofmann, W1
Nicotera, AG1
Dicanio, D1
Pironti, E1
Bonsignore, M1
Cafeo, A1
Efthymiou, S1
Mondello, P1
Salpietro, V1
Houlden, H1
Di Rosa, G1
Hayes-Ryan, D1
O'Donoghue, K1
McCarthy, C1
Totorika, A1
Meaney, S1
Pang, RD1
Dormanesh, A1
Hoang, Y1
Chu, M1
Allem, JP1
Girón-Ortega, JA1
Márquez-Coello, M1
Gutiérrez-Saborido, D1
Arizcorreta, A1
Cuesta-Sancho, S1
Girón-González, JA1
Dovrat, G1
Pevzner, S1
Berthon, C1
Lerner, A1
Maimon, E1
Vainer, R1
Karpasas, M1
Ben-Elyiahu, Y1
Moisy, P1
Bettelheim, A1
Zilbermann, I1
Vanden Broeck, SMP1
Nelson, DJ1
Collado, A1
Falivene, L1
Cavallo, L1
Cordes, DB1
Slawin, AMZ1
Van Hecke, K1
Nahra, F1
Cazin, CSJ1
Nolan, SP1
Kranidiotis-Hisatomi, N1
Yi, H1
Oestreich, M1
Kwiezinski, C1
Weller, C1
van Pinxteren, D1
Brüggemann, M1
Mertes, S1
Stratmann, F1
Herrmann, H1
Treggiari, D1
Tridello, G1
Menin, L1
Borruso, A1
Pintani, E1
Iansa, P1
Cipolli, M1
Melotti, P1
Ren, L1
Liu, L3
Shu, X1
Lin, W1
Yang, P1
Chen, J1
Teo, KL1
Xiao, F1
Wang, H1
Yao, T1
Zhao, X1
Yang, X1
Yu, DYW1
Rogach, AL1
Bordet, A1
Leitner, W1
Gao, S1
Xia, F1
Li, B2
Abdul Razak, IB1
Liu, Y1
Lu, K1
Brown, DE1
Wang, R1
Cheng, Y1
Ni, S1
Qu, H1
Xing, H1
Xu, Z1
Zhu, X1
Yuan, M1
Wang, L1
Yu, J1
Li, Y1
Yang, L1
Liu, H1
Cao, L1
Zhang, S1
Zhao, D1
Yan, T1
Yang, G1
Lin, Z1
Luo, M1
Ye, N1
Lee, SW1
Carnicelli, J1
Getya, D1
Gitsov, I1
Phillips, KS1
Ren, D1
Grützmacher, PG1
Suarez, S1
Tolosa, A1
Gachot, C1
Song, G1
Wang, B1
Presser, V1
Mücklich, F1
Anasori, B1
Rosenkranz, A1
Demireva, M1
Armentrout, PB1
Feng, D1
Cao, K1
He, ZZ1
Knibbs, LD1
Jalaludin, B1
Leskinen, A1
Roponen, M1
Komppula, M1
Jalava, P1
Guo, PY1
Xu, SL1
Yang, BY1
Hu, L1
Zeng, XW1
Chen, G1
Yu, HY1
Lin, L1
Dong, G1
Machulkin, AE1
Shafikov, RR1
Uspenskaya, AA1
Petrov, SA1
Ber, AP1
Skvortsov, DA1
Nimenko, EA1
Zyk, NU1
Smirnova, GB1
Pokrovsky, VS1
Abakumov, MA1
Saltykova, IV1
Akhmirov, RT1
Garanina, AS1
Polshakov, VI1
Saveliev, OY1
Ivanenkov, YA1
Aladinskaya, AV1
Finko, AV1
Yamansarov, EU1
Krasnovskaya, OO1
Erofeev, AS1
Gorelkin, PV1
Dontsova, OA1
Beloglazkina, EK1
Zyk, NV1
Khazanova, ES1
Majouga, AG1
Zheng, YK1
Su, BJ1
Wang, YQ1
Wang, HS1
Liao, HB1
Liang, D1
Shataer, D1
Li, J1
Duan, XM1
Xin, XL1
Aisa, HA1
Allu, SR1
Ravotto, L1
Troxler, T1
Vinogradov, SA1
Cheruku, RR1
Tracy, EC1
Tabaczynski, W1
Missert, JR1
Baumann, H1
Pandey, RK1
Rohde, JM1
Karavadhi, S1
Pragani, R1
Fang, Y1
Zhang, W1
McIver, A1
Zheng, H1
Liu, Q1
Davis, MI1
Urban, DJ1
Lee, TD1
Cheff, DM1
Hollingshead, M1
Henderson, MJ1
Martinez, NJ1
Brimacombe, KR1
Yasgar, A1
Zhao, W1
Klumpp-Thomas, C1
Michael, S1
Covey, J1
Moore, WJ1
Stott, GM1
Li, Z1
Simeonov, A1
Jadhav, A1
Frye, S1
Hall, MD1
Shen, M1
Wang, X1
Patnaik, S1
Boxer, MB1
Zhang, H2
Cheng, C1
Huang, B1
Chen, R1
Huang, Y1
Chen, H1
Pei, W1
Katahara, S1
Sugiyama, Y1
Yamane, M1
Komiya, Y1
Sato, T1
Chida, N1
Paul, D1
Madan, V1
Ramirez, O1
Bencun, M1
Stoeck, IK1
Jirasko, V1
Bartenschlager, R1
Yang, S1
K R, J1
Lim, S1
Choi, TG1
Kim, JH1
Akter, S1
Jang, M1
Ahn, HJ1
Kim, HY1
Windisch, MP1
Khadka, DB1
Zhao, C1
Jin, Y1
Kang, I1
Ha, J1
Oh, BC1
Kim, M1
Kim, SS1
Cho, WJ1
Lampa, A1
Ehrenberg, AE1
Gustafsson, SS1
Vema, A1
Kerblom, E1
Lindeberg, G1
Karlén, A1
Danielson, UH1
Sandström, A1
Montpellier, C1
Tews, BA1
Poitrimole, J1
Rocha-Perugini, V1
D'Arienzo, V1
Potel, J1
Zhang, XA1
Rubinstein, E1
Dubuisson, J1
Cocquerel, L1
Korenaga, M1
Hidaka, I1
Nishina, S1
Sakai, A1
Shinozaki, A1
Gondo, T1
Furutani, T1
Kawano, H1
Sakaida, I1
Hino, K1
Angus, AG1
Loquet, A1
Stack, SJ1
Dalrymple, D1
Gatherer, D1
Penin, F1
Patel, AH1
Tsubota, A1
Kumada, H1
Iwabuchi, S1
Osada, T1
Takatori, M1
Yoshida, H1
Martinetti, M1
Pacati, I1
Daielli, C1
Salvaneschi, L1
Maccabruni, A1
Yamamoto, Y1
Yasuoka, A1
Tachikawa, N1
Teruya, K1
Genka, I1
Yamaguchi, M1
Yasuoka, C1
Kikuchi, Y1
Aoki, M1
Oka, S1
Tarao, K1
Hashino, S1
Imamura, M1
Kobayashi, H1
Tanaka, M1
Fukuhara, T1
Fujimoto, H1
Karino, Y1
Yoshida, J1
Sakurada, K1
Matsushima, T1

Reviews

3 reviews available for glycine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

ArticleYear
[Therapeutic strategies for hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Cysteine; Drug Combinations; Drug Therapy, Combination; Genotype; Glycine; Hepaciv

2004
[Long-term interferon (IFN), neominophagen C (SNMC) combination therapy of active liver cirrhosis type C].
    Nihon rinsho. Japanese journal of clinical medicine, 1994, Volume: 52, Issue:7

    Topics: Biomarkers; Cysteine; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Glycine; Hepac

1994
[Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6

    Topics: Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combin

2001

Other Studies

10 other studies available for glycine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

ArticleYear
    Journal of applied social psychology, 2021, Volume: 51, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti-

2021
Glycine Zipper Motifs in Hepatitis C Virus Nonstructural Protein 4B Are Required for the Establishment of Viral Replication Organelles.
    Journal of virology, 2018, 02-15, Volume: 92, Issue:4

    Topics: Cell Line; Glycine; Hepacivirus; Hepatitis C; Humans; Organelles; Protein Structure, Secondary; RNA,

2018
Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
    Journal of medicinal chemistry, 2015, Dec-24, Volume: 58, Issue:24

    Topics: Animals; Antiviral Agents; Cell Line, Tumor; Cyclophilin A; Drug Synergism; Glycine; Hepacivirus; He

2015
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    Topics: Antiviral Agents; Glycine; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Protease Inhibitors;

2010
Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection.
    The Journal of biological chemistry, 2011, Apr-22, Volume: 286, Issue:16

    Topics: Amino Acid Motifs; Animals; Antigens, CD; Biotinylation; Cell Membrane; CHO Cells; Cricetinae; Crice

2011
A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:4

    Topics: Animals; Cysteine; DNA Primers; Dose-Response Relationship, Drug; Drug Combinations; Fatty Liver; Gl

2011
Conserved glycine 33 residue in flexible domain I of hepatitis C virus core protein is critical for virus infectivity.
    Journal of virology, 2012, Volume: 86, Issue:2

    Topics: Amino Acid Sequence; Cell Line; Conserved Sequence; Glycine; Hepacivirus; Hepatitis C; Humans; Molec

2012
Critical role of Val/Gly86 HLA-DRB dimorphism in the neonatal resistance or susceptibility to maternal hepatitis C virus infection.
    The Pediatric infectious disease journal, 1997, Volume: 16, Issue:10

    Topics: Female; Gene Frequency; Glycine; Haplotypes; Hepatitis C; HLA-DR Antigens; Humans; Infant, Newborn;

1997
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Japanese journal of infectious diseases, 1999, Volume: 52, Issue:6

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy,

1999
[Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1989, Volume: 30, Issue:11

    Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Glycine; G

1989